Merck Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics
– Adds to Merck’s lipid manufacturing expertise, providing an integrated offering across mRNA value chain – AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing – Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing Merck portfolio Merck, a […]
